Head-to-head · free
Novartis vs AbCellera Biologics Inc.
A vs ABCL — return on capital, cash generation, margins and balance sheet side by side.
A
7 / 8
measures where A leads
ABCL
1 / 8
measures where ABCL leads
A simple count of which company scores better on each measure — not a recommendation to buy or sell.
| Measure | A · FY2025 | ABCL · FY2025 |
|---|---|---|
| Revenue | $6.9B | $75.1M |
| Net income | $1.3B | (146.4M) |
| Revenue growth (yearly, multi-year) | 2.4% | -33.1% |
| Free cash flow | $1.2B | (174.1M) |
| Free cash flow margin | 16.6% | -231.7% |
| Net cash / (debt) | — | — |
| ROIC | 13.9% | — |
| Return on equity | 20.6% | -14.5% |
| Gross margin | 52.4% | — |
| Operating margin | 21.3% | -270.5% |
| Net debt / EBITDA | 0.89x | 0.68x |
Figures are as reported by each company; latest fiscal year shown.
Where Novartis's cash went (FY2025)
- Capital spending
- $407.0M
- Buybacks
- —
- Dividends
- —
- Acquisitions
- —
- Net debt issued / (repaid)
- —
Where AbCellera Biologics Inc.'s cash went (FY2025)
- Capital spending
- $42.8M
- Buybacks
- —
- Dividends
- —
- Acquisitions
- —
- Net debt issued / (repaid)
- —
Ask which business is stronger
"Which one reinvests at higher returns?" "Who carries more risk in its filings?" Get answers drawn straight from both companies' filings.
Compare them free